2026.03.12 (목)

  • 구름많음속초4.5℃
  • 맑음6.4℃
  • 맑음철원5.7℃
  • 맑음동두천7.2℃
  • 맑음파주8.0℃
  • 구름많음대관령-1.3℃
  • 맑음춘천7.0℃
  • 맑음백령도3.4℃
  • 비북강릉2.0℃
  • 흐림강릉2.0℃
  • 흐림동해3.3℃
  • 맑음서울10.1℃
  • 맑음인천7.2℃
  • 맑음원주8.1℃
  • 맑음울릉도3.5℃
  • 맑음수원8.4℃
  • 맑음영월5.2℃
  • 맑음충주8.3℃
  • 맑음서산6.1℃
  • 흐림울진1.6℃
  • 맑음청주10.7℃
  • 구름많음대전10.6℃
  • 흐림추풍령6.1℃
  • 맑음안동6.9℃
  • 구름많음상주8.6℃
  • 흐림포항7.2℃
  • 맑음군산7.7℃
  • 흐림대구7.8℃
  • 맑음전주8.2℃
  • 맑음울산6.0℃
  • 맑음창원9.8℃
  • 연무광주8.9℃
  • 맑음부산8.5℃
  • 맑음통영8.2℃
  • 맑음목포5.6℃
  • 구름많음여수9.6℃
  • 맑음흑산도5.3℃
  • 맑음완도7.4℃
  • 맑음고창5.0℃
  • 구름많음순천8.3℃
  • 맑음홍성(예)8.6℃
  • 구름많음9.1℃
  • 맑음제주9.0℃
  • 맑음고산7.6℃
  • 맑음성산8.3℃
  • 맑음서귀포10.4℃
  • 맑음진주9.6℃
  • 맑음강화8.1℃
  • 맑음양평9.7℃
  • 구름많음이천9.5℃
  • 맑음인제3.9℃
  • 맑음홍천6.8℃
  • 구름많음태백0.1℃
  • 맑음정선군3.7℃
  • 맑음제천3.9℃
  • 구름많음보은9.0℃
  • 구름많음천안9.9℃
  • 맑음보령7.0℃
  • 맑음부여10.4℃
  • 구름많음금산8.5℃
  • 맑음10.2℃
  • 맑음부안5.8℃
  • 맑음임실7.2℃
  • 맑음정읍7.2℃
  • 맑음남원8.1℃
  • 구름많음장수7.7℃
  • 맑음고창군5.3℃
  • 맑음영광군5.0℃
  • 맑음김해시7.7℃
  • 맑음순창군8.2℃
  • 맑음북창원10.3℃
  • 맑음양산시9.3℃
  • 구름많음보성군8.0℃
  • 구름많음강진군8.1℃
  • 구름많음장흥8.7℃
  • 맑음해남6.2℃
  • 구름많음고흥9.5℃
  • 맑음의령군7.0℃
  • 흐림함양군9.0℃
  • 구름많음광양시8.6℃
  • 맑음진도군5.7℃
  • 구름많음봉화3.5℃
  • 맑음영주6.7℃
  • 흐림문경7.5℃
  • 맑음청송군5.1℃
  • 구름많음영덕4.4℃
  • 맑음의성7.0℃
  • 구름많음구미8.2℃
  • 맑음영천8.1℃
  • 맑음경주시6.8℃
  • 맑음거창7.7℃
  • 맑음합천9.1℃
  • 맑음밀양9.3℃
  • 구름많음산청9.3℃
  • 맑음거제9.1℃
  • 맑음남해6.9℃
  • 맑음9.0℃
기상청 제공
Shoppy 로고
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
  • 해당된 기사를 공유합니다

Cancellation of remaining publicly held registered shares of Vifor Pharma AG

Last trading day of Vifor registered shares: 22 December 2022
Delisting date of Vifor registered shares: 23 December 2022

Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a “Vifor Share”). The Commercial Court's decision has become legally effective (rechtskräftig) and is published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt; SHAB) by the Commercial Court.

Vifor further announced today that SIX Exchange Regulation AG has determined the last trading day and the delisting date of the Vifor Shares at and from SIX Swiss Exchange as follows:

Last trading day: 22 December 2022

Delisting date: 23 December 2022

As a result of the cancellation of the remaining publicly held Vifor Shares, each holder of cancelled Vifor Shares is entitled to a compensation of USD 179.25 in cash per cancelled Vifor Share. The envisaged settlement date for payment of such compensation against delivery of the cancelled Vifor Shares is 28 December 2022.

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.

Forward-Looking Statements

This announcement may contain statements that constitute forward-looking statements. The words “anticipate”, “believe”, “expect”, “estimate”, “aim”, “project”, “forecast”, “estimate”, “risk”, “likely”, “intend”, “outlook”, “should”, “could”, “would”, “may”, “will”, “continue”, “plan”, “probability”, “indicative”, “seek”, “target”, “plan” and other similar expressions are intended to identify forward-looking statements.

Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of CSL and Vifor and their officers, employees, agents and advisors, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and may cause actual results to differ materially from those expressed or implied in such statements. You are strongly cautioned not to place undue reliance on forward-looking statements.

This announcement is not a financial product or investment advice, a recommendation to acquire or sell securities or accounting, legal or tax advice. It does not constitute an invitation or offer to apply for securities. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate for their jurisdiction. CSL and Vifor are not licensed to provide financial product advice in respect of an investment in securities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005876/en/

언론연락처: CSL Vifor Media Contact Thomas Hutter Mobile: +41 79 957 96 73 Investor Contact CSL Limited Steve McKeon Associate Director, Investor Relations Mobile +61 402 231 696 Switzerland / Europe Martin Meier-Pfister (IRF) + 41 432 448 140

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기